HIV-associated sensory neuropathy: still a problem in the post-stavudine era?

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Keswani S, Pardo C, Cherry C, Hoke A, McArthur J. HIV-associated sensory neuropathies. AIDS16(16),2105–2117 (2002).
  MedlineGoogle Scholar
• 2  Kamerman P, Wadley A, Cherry C. HIV-associated sensory neuropathy: risk factors and genetics. Curr. Pain Headache Rep.16(3),226–236 (2012).▪ Recent review providing a succinct, up-to-date summary of the published associations between epidemiologic factors (including host genetics) and HIV-associated sensory neuropathy (HIV-SN).
  MedlineGoogle Scholar
• 3  Wadley A, Cherry C, Price P, Kamerman P. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J. Pain Symptom. Manage.41(4),700–706 (2010).
  MedlineGoogle Scholar
• 4  Smyth K, Affandi J, McArthur J et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med.8(6),367–373 (2007).▪ Describes three cross-sectional HIV-SN screening programs undertaken between 1993 and 2006 at one clinic in Melbourne, Australia. Importantly, the prevalence of symptomatic HIV-SN in 2006 (42%) was unchanged compared with 2001 (44%), despite a marked reduction in stavudine use.
  Medline CASGoogle Scholar
• 5  Maritz J, Benatar M, Dave J et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve41(5),599–606 (2010).
  MedlineGoogle Scholar
• 6  Beadles W, Jahn A, Weigel R, Clutterbuck D. Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop. Doct.39(2),78–80 (2009).
  Medline CASGoogle Scholar
• 7  Cherry C, Affandi J, Imran D et al. Age and height predict neuropathy risk in HIV patients prescribed stavudine. Neurology73(4),315–320 (2009).
  Medline CASGoogle Scholar
• 8  Meyer-Rosberg K, Kvarnström A, Kinnman E, Gordh T, Nordfors L, Kristofferson A. Peripheral neuropathic pain-a multidimensional burden for patients. Eur. J. Pain5(4),379–389 (2001).
  Medline CASGoogle Scholar
• 9  Dworkin R, O’connor A, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc.85(Suppl. 3),S3–S14 (2010).
  Medline CASGoogle Scholar
• 10  Finnerup N, Sindrup S, Jensen T. The evidence for pharmacological treatment of neuropathic pain. Pain150(3),573–581 (2010).
  MedlineGoogle Scholar
• 11  Phillips T, Cherry C, Cox S, Marshall S, Rice A. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One5(12),e14433 (2010).▪ Systematic review of randomized, controlled trials of pharmacological treatments for HIV-SN, highlighting the lack of evidence-based therapies for neuropathic pain in HIV and the need for more studies in this area.
  Medline CASGoogle Scholar
• 12  Clifford D, Simpson D, Brown S et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J. Acquir. Immune Defic. Syndr.59(2),126–133 (2012).
  Medline CASGoogle Scholar
• 13  Barohn R, Gronseth G, Leforce B et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol.50,167–170 (1993).
  Medline CASGoogle Scholar
• 14  Woolley I, Faragher M, Ugoni A, Spelman D. An analysis of factors associated with HIV-related peripheral neuropathy. Neurol. Infect. Epidemiol.2,33–37 (1997).
  Google Scholar
• 15  Childs E, Lyles R, Selnes O et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology52,607–613 (1999).
  Medline CASGoogle Scholar
• 16  So Y, Holtzman D, Abrams D, Olney R. Peripheral neuropathy associated with acquired immunodeficiency syndrome - prevalence and clinical features from a population-based survey. Arch Neurol.45(9),945–948 (1988).
  Medline CASGoogle Scholar
• 17  Ellis R, Badiee J, Vaida F et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS25(14),1747–1751 (2011).
  Medline CASGoogle Scholar
• 18  Thompson M, Aberg J, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA304(3),321–333 (2010).
  Medline CASGoogle Scholar
• 19  Ances B, Vaida F, Rosario D et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS23(17),2317–2322 (2009).
  Medline CASGoogle Scholar
• 20  Kumarasamy N, Venkatesh K, Cecelia A et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS22(4),227–244 (2008).
  Google Scholar
• 21  WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. WHO, Geneva, Switzerland (2009).
  Google Scholar
• 22  Hahn K, Triolo A, Hauer P, McArthur J, Polydefkis M. Impaired reinnervation in HIV infection following experimental denervation. Neurology68(16),1251–1256 (2007).▪ Important study demonstrating impaired nerve regeneration following capsaicin ablation of cutaneous nerves in individuals with HIV infection. Even those without HIV-SN demonstrated impaired neuroregeneration compared with HIV-negative controls.
  Medline CASGoogle Scholar
• 23  Mills E, Bakanda C, Birungi J et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann. Intern. Med.155(4),209–216 (2011).
  MedlineGoogle Scholar
• 24  Van Sighem A, Gras L, Reiss P, Brinkman K, De Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS24(10),1527–1535 (2010).
  MedlineGoogle Scholar
• 25  Watters M, Poff P, Shiramizu B et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology62(8),1376–1383 (2004).
  Google Scholar
• 26  Morgello S, Estanislao L, Simpson D et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. The Manhattan HIV Brain Bank. Arch Neurol.61(4),546–551 (2004).
  MedlineGoogle Scholar
• 27  Affandi J, Price P, Imran D, Yuhaningsih E, Djauzi S, Cherry C. Can we predict neuropathy risk before stavudine prescription in a resource limited setting? AIDS Res. Hum. Retroviruses24(10),1281–1284 (2008).
  Medline CASGoogle Scholar
• 28  Evans S, Ellis R, Chen H et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS25(7),919–928 (2011).
  MedlineGoogle Scholar
• 29  Nakamoto B, McMurtray A, Davis J et al. Incident neuropathy in HIV-infected patients on HAART. AIDS Res. Hum. Retroviruses26(7),759–765 (2010).
  Medline CASGoogle Scholar
• 30  Lessells R, Mutevedzi P, Cooke G, Newell M. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J. Acquir. Immune Defic. Syndr.56(3),e79–e86 (2011).
  Medline CASGoogle Scholar
• 31  Gallant J, Dejesus E, Arribas J et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med.354,251–260 (2006).
  Medline CASGoogle Scholar
• 32  Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA292(2),191–201 (2004).
  Medline CASGoogle Scholar
• 33  Sax P, Tierney C, Collier A et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N. Engl. J. Med.361,2230–2240 (2009).
  Medline CASGoogle Scholar
• 34  Sacktor N, Nakasujja N, Skolasky R et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology72(2),165–170 (2009).
  Medline CASGoogle Scholar
• 35  Forna F, Liechty C, Solberg P et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J. Acquir. Immune Defic. Syndr.44(4),456–462 (2007).
  Medline CASGoogle Scholar
• 36  Ellis R, Rosario D, Clifford D et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol.67(5),552–558 (2010).▪ The CHARTER study is providing systematically collected data on the rates, severity and risks associated with neurological disease among adults with HIV infection in the USA. This paper represents the largest description of HIV-SN rates in adults never exposed to neurotoxic antiretroviral medications, with 741 such patients included in this publication. A total of 45% of them were found to have neuropathic signs consistent with HIV-SN.
  MedlineGoogle Scholar
• 37  Cherry C, Affandi J, Brew B et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among HIV patients. Neurology74(19),1538–1542 (2010).
  Medline CASGoogle Scholar
• 38  WHO. UNAIDS World AIDS Day Report. WHO, Geneva, Switzerland (2011)
  Google Scholar
• 39  Cherry C, Wesselingh S, Lal L, McArthur J. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology65(11),1778–1781 (2005).▪ The lack of accepted ‘gold standard’ diagnostic criteria for HIV-SN presents problems in epidemiologic research. This paper provides evidence that a very simple clinical tool (the ACTG Brief Peripheral Neuropathy Screen) is an appropriate tool for the research diagnosis of HIV-SN. Individuals with both symptoms and signs of neuropathy on this tool were shown to have greater pathology and increased impaired peripheral nerve function than others with HIV.
  MedlineGoogle Scholar
• 40  Ellis R, Marquie-Beck J, Delaney P et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann. Neurol.64(5),566–572 (2008).
  Medline CASGoogle Scholar
• 41  Pettersen J, Jones G, Worthington C et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann. Neurol.59(5),816–824 (2006).
  Medline CASGoogle Scholar
• 42  Cherry C, Affandi J, Rosenow A, McArthur J, Wesselingh S, Price P. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual’s NRTI-SN risk. AIDS Res. Hum. Retroviruses24(2),117–123 (2008).
  Medline CASGoogle Scholar
• 43  Chew C, Cherry C, Imran D et al. Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients. Tissue Antigens77(2),126–130 (2010).
  MedlineGoogle Scholar
• 44  Banerjee S, Mccutchan J, Ances B et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS25(2),F1–F6 (2011).
  Medline CASGoogle Scholar
• 45  Sacktor N, Nakasujja N, Skolasky R et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin. Infect. Dis.49(5),780–786 (2009).
  MedlineGoogle Scholar
• 46  Zheng W, Ouyang H, Zheng X et al. Glial TNFα in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats. Mol. Pain.7,40 (2011).
  Medline CASGoogle Scholar
• 47  Höke A, Morris M, Haughey N. GPI-1046 protects dorsal root ganglia from gp120-induced axonal injury by modulating store-operated calcium entry. J. Peripher. Nerv. Syst.14(1),27–35 (2009).
  Medline CASGoogle Scholar
• 48  Wallace V, Blackbeard J, Segerdahl A et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain130(10),2688–2702 (2007).▪ Looks at pathological features in rodent models of neuropathy triggered by viral factors, drugs or a combination of both. Provides a useful example of how a complex disease process can be deconstructed through well-designed animal experiments ([61], from the same group, is another good example of this).
  MedlineGoogle Scholar
• 49  Wallace V, Blackbeard J, Pheby T et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain133(1–3),47–63 (2007).
  Medline CASGoogle Scholar
• 50  Attal N, Bouhassira D, Baron R et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur. J. Pain15(5),441–443 (2011).
  MedlineGoogle Scholar
• 51  Lauria G, Hsieh S, Johansson O et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol.17(7),903–912 (2010).
  Medline CASGoogle Scholar
• 52  Maier C, Baron R, Tölle T et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain150(3),429–450 (2010).
  Google Scholar
• 53  Baron R, Tölle T, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia. Differences in demographic data and sensory symptoms. Pain146(1–2),34–40 (2009).
  MedlineGoogle Scholar
• 54  Simpson D, Schifitto G, Clifford D et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology74(5),413–420 (2010).
  Medline CASGoogle Scholar
• 55  Laast V, Shim B, Johanek L et al. Macrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques. Am. J. Pathol.179(5),2337–2345 (2011).
  MedlineGoogle Scholar
• 56  Kamerman P, Moss P, Weber J, Wallace V, Rice A, Huang W. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J. Peripher. Nerv. Syst.17(1),19–31 (2012).▪ Recent review providing a succinct, up-to-date discussion of the pathogenesis of HIV-SN and its primary symptom, pain, based on evidence obtained from in vivo and in vitro experimental models of the neuropathy.
  Medline CASGoogle Scholar
• 57  Anderson T, Davidovich A, Arceo R, Brosnan C, Arezzo J, Schaumbureg H. Peripheral neuropathy induced by 2´,3´-dideoxycytidine. A rabbit model of 2´,3´-dideoxycytidine neurotoxicity. Lab. Invest.66(1),63–74 (1992).
  Medline CASGoogle Scholar
• 58  Anderson T, Davidovich A, Feldman D et al. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab. Invest.70(5),724–739 (1994).
  Medline CASGoogle Scholar
• 59  Feldman D, Brosnan C, Anderson T. Ultrastructure of peripheral neuropathy induced in rabbits by 2´,3´-dideoxycytidine. Lab. Invest.66(1),75–85 (1992).
  Medline CASGoogle Scholar
• 60  Wallace V, Segerdahl A, Blackbeard J, Pheby T, Rice A. Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neurosci. Lett.448(1),153–156 (2008).
  Medline CASGoogle Scholar
• 61  Maratou K, Wallace V, Hasnie F et al. Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur. J. Pain13(4),387–398 (2009).
  Medline CASGoogle Scholar
• 62  Wallace V, Segerdahl A, Lambert D et al. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. Br. J. Pharmacol.151(7),1117–1128 (2007).
  Medline CASGoogle Scholar
• 63  Power C, Hui E, Vivithanaporn P, Acharjee S, Polyak M. Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr. J. Neuroimmune Pharmacol.7(2),319–331 (2012).
  MedlineGoogle Scholar